Comparative safety of antiepileptic drugs for neurological development in children exposed during pregnancy and breast feeding: a systematic review and network meta-analysis
Open accessThe DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index; 8 of the 28 sources its claims cite were checked for support.
Abstract
Objectives: Compare the safety of antiepileptic drugs (AEDs) on neurodevelopment of infants/children exposed in utero or during breast feeding. Design and setting: Systematic review and Bayesian random-effects network meta-analysis (NMA). MEDLINE, EMBASE and the Cochrane Central Register of Controlled Trials were searched until 27 April 2017. Screening, data abstraction and quality appraisal were completed in duplicate by independent reviewers. Participants: 29 cohort studies including 5100 infants/children. Interventions: Monotherapy and polytherapy AEDs including first-generation (carbamazepine, clobazam, clonazepam, ethosuximide, phenobarbital, phenytoin, primidone, valproate) and newer-generation (gabapentin, lamotrigine, levetiracetam, oxcarbazepine, topiramate, vigabatrin) AEDs. Epileptic women who did not receive AEDs during pregnancy or breast feeding served as the control group. Primary and secondary outcome measures: Cognitive developmental delay and autism/dyspraxia were primary outcomes. Attention-deficit hyperactivity disorder, language delay, neonatal seizures, psychomotor developmental delay and social impairment were secondary outcomes. Results: The NMA on cognitive developmental delay (11 cohort studies, 933 children, 18 treatments) suggested that among all AEDs only valproate was statistically significantly associated with more children experiencing cognitive developmental delay compared with control (OR=7.40, 95% credible interval (CrI) 3.00 to 18.46). The NMA on autism (5 cohort studies, 2551 children, 12 treatments) suggested that oxcarbazepine (OR 13.51, CrI 1.28 to 221.40), valproate (OR 17.29, 95% CrI 2.40 to 217.60), lamotrigine (OR 8.88, CrI 1.28 to 112.00) and lamotrigine+valproate (OR 132.70, CrI 7.41 to 3851.00) were associated with significantly greater odds of developing autism compared with control. The NMA on psychomotor developmental delay (11 cohort studies, 1145 children, 18 treatments) found that valproate (OR 4.16, CrI 2.04 to 8.75) and carbamazepine+phenobarbital+valproate (OR 19.12, CrI 1.49 to 337.50) were associated with significantly greater odds of psychomotor delay compared with control. Conclusions: Valproate alone or combined with another AED is associated with the greatest odds of adverse neurodevelopmental outcomes compared with control. Oxcarbazepine and lamotrigine were associated with increased occurrence of autism. Counselling is advised for women considering pregnancy to tailor the safest regimen. Trial registration number: PROSPERO database (CRD42014008925).
Overview
CoChat Summary
TL;DR
This systematic review and Bayesian network meta-analysis of 29 cohort studies (5100 children) found that valproate alone or combined with another AED was associated with the greatest odds of adverse neurodevelopmental outcomes. Oxcarbazepine and lamotrigine were also associated with increased autism/dyspraxia.
Key findings
- Cognitive developmental delay NMA (11 cohort studies, 933 children, 18 treatments): only valproate was significantly associated with more children experiencing cognitive developmental delay versus control (OR 7.40, 95% CrI 3.00 to 18.46).
- Autism/dyspraxia NMA (5 cohort studies, 2551 children, 12 treatments): oxcarbazepine (OR 13.51, CrI 1.28 to 221.40), valproate (OR 17.29, 95% CrI 2.40 to 217.60), lamotrigine (OR 8.88, CrI 1.28 to 112.00) and lamotrigine+valproate (OR 132.70, CrI 7.41 to 3851.00) were associated with significantly greater odds of autism/dyspraxia versus control.
- Psychomotor developmental delay NMA (11 cohort studies, 1145 children, 18 treatments): valproate (OR 4.16, CrI 2.04 to 8.75) and carbamazepine+phenobarbital+valproate (OR 19.12, CrI 1.49 to 337.50) were associated with significantly greater odds versus control.
- Language delay NMA (5 cohort studies, 509 children, 5 treatments): valproate was the only treatment significantly associated with increased odds (OR 7.95, 95% CrI 1.50 to 49.13). ADHD NMA (5 cohort studies, 816 children, 7 treatments) found no treatment comparisons reached statistical significance.
Methods
- Systematic review and Bayesian random-effects network meta-analysis; MEDLINE, EMBASE and Cochrane Central Register of Controlled Trials searched until 27 April 2017; screening, data abstraction and quality appraisal completed in duplicate; registered with PROSPERO (CRD42014008925).
- Included 29 cohort studies (5100 infants/children) of mothers consuming AEDs during pregnancy and/or breastfeeding; monotherapy and polytherapy first-generation and newer-generation AEDs were eligible; control was epileptic women who did not receive AEDs; primary outcomes were cognitive developmental delay and autism/dyspraxia, with secondary outcomes including ADHD, language delay, neonatal seizures, psychomotor developmental delay and social impairment.
- Used ORs for dichotomous outcomes, hierarchical meta-analysis and NMA models in a Bayesian framework (OpenBUGS), random-effects models, transitivity and consistency assessments, network meta-regression and sensitivity analyses, and SUCRA rankings.
Limitations
- Stated in the paper: drug dosages could not be accounted for, and different dosages of the same AED were assumed equally effective; when a study reported multiple dosages for the same treatment, data were combined.
- Stated in the paper: several polytherapies had high SUCRA estimates but very wide credible intervals due to small numbers of studies and underpowered sample sizes; ranking probabilities may be biased toward treatments with the smallest number of studies.
- Stated in the paper: no RCT evidence was available, so conclusions were based on observational studies only, with inherent confounding and shortcomings; important effect modifiers were often unreported (eg, family history of autism, ADHD, maternal IQ, severity of epilepsy), and subgroup analysis by exposure type (breastfeeding vs in utero) could not be conducted because 22 studies did not report breastfeeding exposure. Evident from the text: many NMAs included small numbers of studies/children, credible intervals were wide, and methodological quality was imbalanced across treatment comparisons.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
5 Valid · 0 Not valid · 13 Not checked · 67 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“AED use during pregnancy is associated with risks to the fetus as these drugs can cross the placenta or may be transferred to the infant through breast feeding and may be associated with adverse neurodevelopment outcomes.2–4”
§ Comparative safety of antiepileptic drugs for neurological development in children exposed during pregnancy and breast feeding: a systematic review and network meta-analysis > Introduction
What the sources say
- Partly supportedcites [2] Harden CL, Pennell PB, Koppel BS, et al Management issues for women with epilepsy--focus on pregnancy (an evidence-based review): III. Vitamin K, folic acid, blood levels, and breast-feeding: Report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Epilepsia 2009; 50: 1247– 55. 19507305 sourceExperimental — accuracy not yet measured
The Conclusions and Clinical context sections report that many AEDs cross the placenta or enter breast milk. But Recommendations for Future Research says studies did not systematically evaluate outcomes such as cognition and neonatal development. This source therefore supports the exposure pathways, not an association with adverse neurodevelopmental outcomes. (LLM, conf=0.86)
- Could not verifycites [3] Samrén EB, van Duijn CM, Koch S, et al Maternal use of antiepileptic drugs and the risk of major congenital malformations: a joint European prospective study of human teratogenesis associated with maternal epilepsy. Epilepsia 1997; 38: 981– 90. 10.1111/j.1528-1157.1997.tb01480.x 9579936 sourceExperimental — accuracy not yet measured
The Abstract and Results report an association between prenatal AED exposure and major congenital malformations, not adverse neurodevelopmental outcomes. A search for cognitive or developmental outcomes found no assessment of those outcomes in our copy; congenital malformations alone do not establish the attributed neurodevelopmental association. (LLM, conf=0.76)
- Could not verifycites [4] Meador K, Reynolds MW, Crean S, et al Pregnancy outcomes in women with epilepsy: a systematic review and meta-analysis of published pregnancy registries and cohorts. Epilepsy Res 2008; 81: 1– 13. 10.1016/j.eplepsyres.2008.04.022 18565732 PMC2660205 sourceExperimental — accuracy not yet measured
The Introduction and Discussion address congenital malformations and other pregnancy outcomes associated with in-utero AED exposure, but do not report neurodevelopmental outcomes in children. Searches for neurodevelopment, cognition, and developmental delay found no passage in the paper's substantive text that establishes the claimed association. (LLM, conf=0.76)
hedgedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“However, there is a lack of sufficiently powered studies to assess the impact of AEDs on neurodevelopment in children of women exposed to these agents, especially for newer-generation drugs, thus highlighting the need for a systematic review.9 10”
§ Comparative safety of antiepileptic drugs for neurological development in children exposed during pregnancy and breast feeding: a systematic review and network meta-analysis > Introduction
What the sources say
- Partly supportedcites [9] Wlodarczyk BJ, Palacios AM, George TM, et al Antiepileptic drugs and pregnancy outcomes. Am J Med Genet A 2012; 158A: 2071– 90. 10.1002/ajmg.a.35438 22711424 PMC3402584 sourceExperimental — accuracy not yet measured
The Introduction (page unavailable) says most studies of AED teratogenic effects are too small and underpowered, and that risks of newer drugs remain unknown because of small sample sizes and polytherapy exposure. It also discusses neurodevelopmental deficits after valproate exposure, but the cited passages do not specifically establish a lack of sufficiently powered studies of children’s neurodevelopment, particularly for newer-generation AEDs. (LLM, conf=0.84)
- Supportedcites [10] Velez-Ruiz NJ, Meador KJ Neurodevelopmental effects of fetal antiepileptic drug exposure. Drug Saf 2015; 38: 271– 8. 10.1007/s40264-015-0269-9 25693658 PMC4376625 source
The Human Studies limitations section says some studies had small samples and that large studies are needed to assess less frequent outcomes. The Conclusions section says the cognitive and behavioral risks of fetal exposure to other AEDs remain unknown because adequate human data are lacking, supporting the particular concern about newer drugs. The cited paper does report established findings for some AEDs, so the claim is best read as a statement about gaps in the evidence, not a complete absence of studies. (LLM, conf=0.88)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Our results are supported by findings from a cohort study, which found that children exposed to levetiracetam were not at increased risk for delayed development compared with unexposed children (see online supplementary appendix C).42”
§ Comparative safety of antiepileptic drugs for neurological development in children exposed during pregnancy and breast feeding: a systematic review and network meta-analysis > Discussion
What the sources say
- Supportedcites [42] Shallcross R, Bromley RL, Irwin B, et al Child development following in utero exposure: levetiracetam vs sodium valproate. Neurology 2011; 76: 383– 9. 10.1212/WNL.0b013e3182088297 21263139 PMC3271390 source
The Abstract (Conclusion) of our copy states directly that children exposed to LEV in utero are not at increased risk of delayed development, and the Results (p. ~7, passage on overall developmental ability) show LEV-exposed children did not differ from the control group (p = 0.62), with 8% below average vs 12% in controls. The control group is defined in Methods as children born to women without epilepsy and not exposed to medication in pregnancy (n = 97), i.e. unexposed children, and the study is described as a prospective observational cohort recruited from 2 UK cohorts, matching 'cohort study'. The only qualifier the citing sentence drops is the source's age/domain bound ('early cognitive development under the age of 24 months'), which does not alter the attributed comparison. (LLM, conf=0.92)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The NMA on cognitive developmental delay (11 cohort studies, 933 children, 18 treatments) suggested that among all AEDs only valproate was statistically significantly associated with more children experiencing cognitive developmental delay compared with control (OR=7.40, 95% credible interval (CrI) 3.00 to 18.46).”
- Also stated in: § Cognitive developmental delay · plain
“Across all AEDs, only valproate was associated with significantly increased odds of cognitive developmental delay compared with control (OR 7.40, 95% CrI 3.00 to 18.46; figure 2A; see online supplementary appendix H).”
§ Comparative safety of antiepileptic drugs for neurological development in children exposed during pregnancy and breast feeding: a systematic review and network meta-analysis > Abstract > Results
plainstates an associationn = 933- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on 2 assumptions not shown here.
- Also stated in: § Cognitive developmental delay · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“29 cohort studies including 5100 infants/children.”
- Also stated in: § Study and patient characteristics · plain
“We included 29 cohort studies (5100 patients) published between 1989 and 2016”
- Also stated in: § Trial registration number · plain
“Twenty-nine cohort studies involving 5100 children of women who took antiepileptic drugs (AEDs) were included in this systematic review.”
§ Comparative safety of antiepileptic drugs for neurological development in children exposed during pregnancy and breast feeding: a systematic review and network meta-analysis > Abstract > Participants
plainn = 5,100- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Study and patient characteristics · plain
40 more claims
Create a free account to see all 85 claims and to verify the 20 references still open.
- Probably not a substantial claim. 19
- It may state two separate claims as one. 24
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Important is also that the anti-epileptic drugs, given at young age or during pregnancy, can have major neurodevelopmental implications as well.”
From Development of prefrontal cortex (2022) · cites this paper as [393]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“reporting that only valproate was associated with more children experiencing cognitive developmental delay compared with controls (OR 7.40, 95% CI 3.00–18.46).”
From The contribution of environmental exposure to the etiology of autism spectrum disorder (2019) · cites this paper as [128]
In the citing paper
“In a subset of studies examining autism risk (5 cohort studies, 2551 children, 12 treatments), this risk was amplified (OR 17.29, 95% CI 2.40–217.60) [128].”
From The contribution of environmental exposure to the etiology of autism spectrum disorder (2019) · cites this paper as [128]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“| Cognitive developmental delay | 12 | 58.62 |”
§ Comparative safety of antiepileptic drugs for neurological development in children exposed during pregnancy and breast feeding: a systematic review and network meta-analysis > Results > Study and patient characteristics
Reported 58.62 · recomputed 41.37931
Citations
Cites
Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series
(2008) · doi:10.1002/9780470712184 · Cited by 25,048 · cited 1×
“Strengths of our study include a comprehensive systematic review methodology that followed the Cochrane Handbook 44 and ISPOR 12 guidelines, and reported using the PRISMA extension for NMA.”
MethodDermyshi, E., Wang, Y., Yan, C., Hong, W., Qiu, G., Gong, X., & Zhang, T. (2017) · Neonatology · doi:10.1159/000454668 · Cited by 24,451
(2014) · Medical Entomology and Zoology · Cited by 17,633
Hutton, B., Salanti, G., Caldwell, D. M., Chaimani, A., Schmid, C. H., Cameron, C., Ioannidis, J. P. A., Straus, S., Thorlund, K., Jansen, J. P., et al. (2015) · Annals of Internal Medicine · doi:10.7326/m14-2385 · Cited by 8,269 · cited 3×
“Strengths of our study include a comprehensive systematic review methodology that followed the Cochrane Handbook(44) and ISPOR(12) guidelines, and reported using the PRISMA extension for NMA.(13) To the best of our knowledge, our study was the first that compared and ranked the safety of AEDs.”
MethodSelf-citationPRESS Peer Review of Electronic Search Strategies: 2015 Guideline Statement
McGowan, J., Sampson, M., Salzwedel, D. M., Cogo, E., Foerster, V., & Lefebvre, C. (2016) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2016.01.021 · Cited by 5,700 · cited 1×
“The search strategy for MEDLINE was peer-reviewed by another librarian using the Peer Review of Electronic Search Strategies (PRESS) checklist 15 and is available in the protocol.”
MethodSelf-citationSalanti, G., Ades, A. E., & Ioannidis, J. P. A. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2010.03.016 · Cited by 3,766
Publication bias in clinical research
Easterbrook, P. J., Gopalan, R., Berlin, J. A., & Matthews, D. R. (1991) · The Lancet · doi:10.1016/0140-6736(91)90201-y · Cited by 3,109 · cited 1×
“Fifth, although the tendency towards small-study effects is greater with observational studies than with randomised trials, 50 the assessment of small-study effects using adjusted funnel plots suggested no evidence for their prevalence.”
BackgroundInterpretation of random effects meta-analyses
Riley, R. D., Higgins, J. P. T., & Deeks, J. J. (2011) · BMJ · doi:10.1136/bmj.d549 · Cited by 2,884 · cited 1×
“28 29 The estimated safety of the included AEDs was ranked using the surface under the cumulative ranking (SUCRA) curve.”
MethodA Re-Evaluation of Random-Effects Meta-Analysis
Higgins, J. P. T., Thompson, S. G., & Spiegelhalter, D. J. (2009) · Journal of the Royal Statistical Society Series A: Statistics in Society · doi:10.1111/j.1467-985x.2008.00552.x · Cited by 2,569 · cited 1×
“28 29 The estimated safety of the included AEDs was ranked using the surface under the cumulative ranking (SUCRA) curve.”
MethodGraphical tools for network meta-analysis in STATA
Chaimani, A., Higgins, J. P. T., Mavridis, D., Spyridonos, P., & Salanti, G. (2013) · PLoS ONE · doi:10.1371/journal.pone.0076654 · Cited by 2,473 · cited 1×
“16 For each outcome with ≥ 10 studies, the comparison-adjusted funnel plot was used to assess small-study effects, 17 where the overall treatment effect for each comparison was estimated under the fixed-effect meta-analysis model.”
Method
Research works printed but not linked: 2
- Bromley R, Baxter N, Calderbank R, et al A comprehensive review of the language abilities of children exposed to valproate or carbamazepine in utero. Texas: American Epilepsy Society, 2010.
- Gogatishvili N, Ediberidze T, Lomidze G, et al Cognitive outcomes of children with fetal antiepileptic drug exposure at the age of 3-6 years-preliminary data 1st 624 Congress of the European Academy of Neurology. Berlin: European Journal of Neurology, 2015: p.329.
Cited by
Barnes, T. R., Drake, R., Paton, C., Cooper, S. J., Deakin, B., Ferrier, I. N., Gregory, C. J., Haddad, P. M., Howes, O. D., Jones, I., et al. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881119889296 · Cited by 606
The contribution of environmental exposure to the etiology of autism spectrum disorder
Bölte, S., Girdler, S., & Marschik, P. B. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-018-2988-4 · Cited by 509
Development of prefrontal cortex
Kolk, S. M., & Rakic, P. (2022) · Neuropsychopharmacology · doi:10.1038/s41386-021-01137-9 · Cited by 378
Bjørk, M.-H., Zoega, H., Leinonen, M. K., Cohen, J. M., Dreier, J. W., Furu, K., Gilhus, N. E., Gissler, M., Hálfdánarson, Ó., Igland, J., et al. (2022) · JAMA Neurology · doi:10.1001/jamaneurol.2022.1269 · Cited by 267
30 years of second-generation antiseizure medications: impact and future perspectives
Perucca, E., Brodie, M. J., Kwan, P., & Tomson, T. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30035-1 · Cited by 261
Headache and pregnancy: a systematic review
on behalf of the European Headache Federation School of Advanced Studies (EHF-SAS), Negro, A., Delaruelle, Z., Ivanova, T. A., Khan, S., Ornello, R., Raffaelli, B., Terrin, A., Reuter, U., & Mitsikostas, D. D. (2017) · The Journal of Headache and Pain · doi:10.1186/s10194-017-0816-0 · Cited by 247
“The treatment with lamotrigine during breastfeeding is safe and no serious adverse effects or cognitive and development alterations have been reported [86].”
BackgroundSex differences in movement disorders
Meoni, S., Macerollo, A., & Moro, E. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-019-0294-x · Cited by 207
Teratogenicity of antiepileptic drugs
Tomson, T., Battino, D., & Perucca, E. (2019) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000659 · Cited by 172
Management of epilepsy in women
Stephen, L. J., Harden, C., Tomson, T., & Brodie, M. J. (2019) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30495-2 · Cited by 164
Gialloreti, L. E., Mazzone, L., Benvenuto, A., Fasano, A., García-Alcón, A., Kraneveld, A. D., Moavero, R., Raz, R., Riccio, M. P., Siracusano, M., et al. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8020217 · Cited by 194
“Moreover, other AED, as oxcarbazepine and lamotrigine (alone or combined with valproate), have been found to be associated with the onset of ASD in the offspring [87].”
BackgroundChristensen, J., Pedersen, L., Sun, Y., Dreier, J. W., Brikell, I., & Dalsgaard, S. (2019) · JAMA Network Open · doi:10.1001/jamanetworkopen.2018.6606 · Cited by 127
Coste, J., Blotière, P., Miranda, S., Mikaeloff, Y., Peyre, H., Ramus, F., Zureik, M., Weill, A., & Dray‐Spira, R. (2020) · Scientific Reports · doi:10.1038/s41598-020-74409-x · Cited by 139
Is providing uncertainty intervals in treatment ranking helpful in a network meta-analysis?
Veroniki, A. A., Straus, S. E., Rücker, G., & Tricco, A. C. (2018) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2018.02.009 · Cited by 87
Self-citationClinical challenges of glioma and pregnancy: a systematic review
van Westrhenen, A., Senders, J. T., Martin, E., DiRisio, A. C., & Broekman, M. L. D. (2018) · Journal of Neuro-Oncology · doi:10.1007/s11060-018-2851-3 · Cited by 80
“These results were confirmed by a meta-analysis on the safety of anti-epileptic drugs for neurological development in exposed children, which showed that only valproate was significantly associated with developmental delay [43].”
ResultKnight, R. A., Wittkowski, A., & Bromley, R. (2021) · Epilepsia · doi:10.1111/epi.16953 · Cited by 61
Treatment and care of women with epilepsy before, during, and after pregnancy: a practical guide
Nucera, B., Brigo, F., Trinka, E., & Kalss, G. (2022) · Therapeutic Advances in Neurological Disorders · doi:10.1177/17562864221101687 · Cited by 71
Epilepsy in Pregnancy—Management Principles and Focus on Valproate
Błaszczyk, B., Miziak, B., Pluta, R. M., & Czuczwar, S. J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031369 · Cited by 81
“Mechanisms of fetal congenital malformations include: conversion of AEDs to toxic, unstable metabolites and folic acid deficiency with subsequent increase in homocysteine levels (see below) [25].”
BackgroundMethodResultInfluentialRelation of in-utero exposure to antiepileptic drugs to pregnancy duration and size at birth
Margulis, A. V., Hernández–Díaz, S., McElrath, T. F., Rothman, K. J., Plana, E., Almqvist, C., D'Onofrio, B. M., & Öberg, A. S. (2019) · PLoS ONE · doi:10.1371/journal.pone.0214180 · Cited by 60
“Antiepileptic drugs also 67 differ in the magnitude of their associations with adverse neurodevelopmental outcomes in the 68 offspring, which also appear to be dose dependent [8-10].”
BackgroundManagement of primary headaches during pregnancy, postpartum, and breastfeeding: A systematic review
Saldanha, I. J., Cao, W., Bhuma, M. R., Konnyu, K. J., Adam, G. P., Mehta, S., Zullo, A. R., Chen, K. K., Roth, J. L., & Balk, E. M. (2021) · Headache The Journal of Head and Face Pain · doi:10.1111/head.14041 · Cited by 50
Morphine in acute coronary syndrome: systematic review and meta-analysis
Duarte, G. S., Nunes-Ferreira, A., Rodrigues, F. B., Pinto, F. J., Ferreira, J. J., Costa, J. N., & Caldeira, D. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-025232 · Cited by 53
“In a conservative approach, we attempted to minimise the impact of observational studies and their bias in the estimates by applying a correction factor previously used in other meta-analysis.(26) 27 Nevertheless, we must recognise that this adjustment is artificial and limits our results.”
BackgroundMethodIn utero exposure to antiepileptic drugs is associated with learning disabilities among offspring
Bech, L., Polcwiartek, C., Kragholm, K. H., Andersen, M. P., Rohde, C., Torp-Pedersen, C. T., Nielsen, J., & Hagstrøm, S. (2018) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2018-318386 · Cited by 46
Valproate in Pregnancy: Recent Research and Regulatory Responses
Andrade, C. (2018) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.18f12351 · Cited by 40
Hjorth, S., Bromley, R., Ystrøm, E., Lupattelli, A., Spigset, O., & Nordeng, H. (2019) · PLoS ONE · doi:10.1371/journal.pone.0219778 · Cited by 44
“Antiepileptic medication (ATC-code N03) was not included in the review, as it has been thoroughly investigated in recent reviews [22,23].”
BackgroundTomson, T., Muraca, G. M., & Razaz, N. (2020) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2020-323028 · Cited by 43
Ceulemans, M., Liekens, S., Calsteren, K. V., Allegaert, K., & Foulon, V. (2019) · Research in Social and Administrative Pharmacy · doi:10.1016/j.sapharm.2019.12.010 · Cited by 37
Atzei, A., Jense, I., Zwart, E., Legradi, J., Venhuis, B. J., van der Ven, L. T. M., Heusinkveld, H. J., & Hessel, E. V. S. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18136717 · Cited by 40
Toledo, M., Mostacci, B., Bosak, M., Jędrzejczak, J., Thomas, R. H., Salas‐Puig, J., Biraben, A., & Schmitz, B. (2020) · Journal of Neurology · doi:10.1007/s00415-020-09809-0 · Cited by 38
Management of Anti-Seizure Medications during Pregnancy: Advancements in The Past Decade
Avachat, C., Barry, J. M., Lyu, X., Sherwin, C. M. T., & Birnbaum, A. K. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14122733 · Cited by 43
“On the other hand, valproate has been shown to have the highest risk for MCM; prenatal exposure to it is associated with an increased risk of autism spectrum disorder [19,20].”
BackgroundOverview and Introduction to Autism Spectrum Disorder (ASD)
Al-Dewik, N. I. E., Al‐Jurf, R., Styles, M., Tahtamouni, S., Al‐Sharshani, D., Alsharshani, M., Ahmad, A. I., Khattab, A., Rifai, H. A., & Qoronfleh, M. W. (2020) · Advances in neurobiology · doi:10.1007/978-3-030-30402-7_1 · Cited by 45
Majhi, S., Kumar, S., & Singh, L. (2022) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527321666220428134802 · Cited by 41
Pathophysiology to Risk Factor and Therapeutics to Treatment Strategies on Epilepsy
Boleti, A. P. D. A., Cardoso, P. H. D. O., Frihling, B. E. F., de Moraes, L. F. R. N., Nunes, E. A. C., Mukoyama, L. T. H., Nunes, E. A. C., Carvalho, C. M. E., Macedo, M. L. R., & Migliolo, L. (2024) · Brain Sciences · doi:10.3390/brainsci14010071 · Cited by 42
“It had been reported that some medications, such as oxcarbazepine, valproate, lamotrigine, and lamotrigine concomitantly valproate, increased the risk of developing ASD in those involved in the study [190].”
BackgroundSharma, V., Sharma, P., & Sharma, S. (2020) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2020.1743684 · Cited by 33
“Other medications, such as lamotrigine, are much safer to use in pregnancy [25].”
BackgroundInfluentialMorales‐Ríos, O., Cicero-Oneto, C. E., García-Ruiz, C., Villanueva‐García, D., Hernández-Hernández, M., Olivar-López, V. B., Jiménez-Juárez, R. N., & Jasso-Gutiérrez, L. (2020) · PLoS ONE · doi:10.1371/journal.pone.0230576 · Cited by 40
Levetiracetam for epilepsy: an evidence map of efficacy, safety and economic profiles
Yi, Z., Wen, C., Cai, T., Xu, L., Zhong, X., Zhan, S., & Zhai, S.-D. (2018) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s181886 · Cited by 37
“65).(48) An observational study by Javed et al(93) indicated a low risk of cognitive side effects of LEV (OR=0.”
Treatment of Women With Epilepsy
Sazgar, M. (2019) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/con.0000000000000713 · Cited by 36
Menon, S., Fodjo, J. N. S., Weckhuysen, S., Bhwana, D. K., NJAMNSHI, A. K., Dekker, M. C. J., & Colebunders, R. (2019) · Seizure · doi:10.1016/j.seizure.2019.08.016 · Cited by 30
Dangers of valproate in pregnancy
Wieck, A., & Jones, S. C. (2018) · BMJ · doi:10.1136/bmj.k1609 · Cited by 29
Mostacci, B., Ranzato, F., Giuliano, L., Neve, A. L., Aguglia, U., Bilo, L., Durante, V., Ermio, C., Monti, G., Zambrelli, E., et al. (2020) · Seizure · doi:10.1016/j.seizure.2020.12.005 · Cited by 27
Loss, C. M., Teodoro, L., Rodrigues, G. D., Moreira, L. R., Peres, F. F., Zuardi, A. W., Crippa, J. A. S., Hallak, J. E. C., & Abílio, V. C. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.635763 · Cited by 34
Cohen, J. M., Alvestad, S., Suarez, E. A., Schaffer, A. L., Selmer, R. M., Havard, A., Bateman, B. T., Cesta, C. E., Zoëga, H., Odsbu, I., et al. (2023) · Neurology · doi:10.1212/wnl.0000000000207996 · Cited by 31
Genotoxicity assessment of antiepileptic drugs (AEDs) in human embryonic stem cells
Kardoost, M., Hajizadeh‐Saffar, E., Ghorbanian, M. T., Ghezelayagh, Z., Bagheri, K. P., Behdani, M., & Habibi‐Anbouhi, M. (2019) · Epilepsy Research · doi:10.1016/j.eplepsyres.2019.106232 · Cited by 25
Christensen, J., Zoëga, H., Leinonen, M. K., Gilhus, N. E., Gissler, M., Igland, J., Sun, Y., Tomson, T., Alvestad, S., Bjørk, M., et al. (2024) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2024.100849 · Cited by 24
Weighing the Risks: the Management of Bipolar Disorder During Pregnancy
Thomson, M., & Sharma, V. (2018) · Current Psychiatry Reports · doi:10.1007/s11920-018-0882-2 · Cited by 24
On the Digital Psychopharmacology of Valproic Acid in Mice
Bass, J. S., Tuo, A., Ton, L. T., Jankovic, M. J., Kapadia, P., Schirmer, C., & Krishnan, V. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.594612 · Cited by 26
“Autistic endophenotypes of the human fetal VPA syndrome (Bromley et al., 2014; Velez-Ruiz and Meador, 2015; Bromley and Baker, 2017; Veroniki et al., 2017) have been ascertained in rodent prenatal VPA protocols using tasks of sociability, social novelty and/or ultrasonic vocalizations (Kazdoba et al.”
BackgroundMethodPhysiological mediators of prenatal environmental influences in autism spectrum disorder
Frye, R. E., Cakir, J., Rose, S., Palmer, R. F., Austin, C. E., & Curtin, P. C. P. (2021) · BioEssays · doi:10.1002/bies.202000307 · Cited by 27
“found to have increased risk of developing ASD when taken during pregnancy.[37] Interestingly, folate supplementation during preg-”
BackgroundBastaki, K., Alwan, S. S., & Zahir, F. (2020) · Advances in neurobiology · doi:10.1007/978-3-030-30402-7_5 · Cited by 28
Epilepsy and pregnancy: What should the neurologists do?
Dupont, S., & Vercueil, L. (2021) · Revue Neurologique · doi:10.1016/j.neurol.2021.01.003 · Cited by 30
Developmental pyrethroid exposure causes a neurodevelopmental disorder phenotype in mice
Curtis, M. A., Dhamsania, R. K., Branco, R. C., Guo, J., Creeden, J. F., Neifer, K. L., Black, C. A., Winokur, E. J., Andari, E., Dias, B. G., et al. (2023) · PNAS Nexus · doi:10.1093/pnasnexus/pgad085 · Cited by 23
Paternal Valproate Use and Neurodevelopmental Disorder and Congenital Malformation Risk in Offspring
Colas, S., Longin, J., Santos, A. C., Kaplan, S., di Giuseppe, R., Bigat, D., Venerus, A., Bjørk, M., Kürzinger, M., Cilio, M. R., et al. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.42581 · Cited by 21
Marxer, C. A., Rüegg, S. J., Rauch, M., Panchaud, A., Meier, C. R., & Spoendlin, J. (2021) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2021.1943355 · Cited by 23
“Given the methodological heterogeneity of existing evidence, we discuss individual studies with their advantages and limitations, rather than published metaanalyses [44,45].”
BackgroundLavu, A., Vaccaro, C., Zusman, E. Z., Aboulatta, L., Aloud, B. M., Alessi‐Severini, S., Haidar, L., Peymani, P., Ng, M., Ruth, C., et al. (2023) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15752 · Cited by 21
Pharmacological Management of the Genetic Generalised Epilepsies in Adolescents and Adults
Stephen, L. J., & Brodie, M. J. (2020) · CNS Drugs · doi:10.1007/s40263-020-00698-5 · Cited by 21
“Valproate use during pregnancy has also been associated with poorer neurodevelopmental outcomes in offspring [132, 136], with more children experiencing cognitive, psychomotor or language developmental delay, compared with children of untreated women with epilepsy [134].”
BackgroundGhoneim, F. M., Alrefai, H., Elsamanoudy, A. Z., El‐khair, S. M. A., & Khalaf, H. A. (2020) · Biology · doi:10.3390/biology9090239 · Cited by 18
“Antiepileptic drugs (AEDs) are commonly used during pregnancy and are prescribed in various drug medication [1,2].”
BackgroundPregnancy and multiple sclerosis: Risk of unplanned pregnancy and drug exposure in utero
Smith, A. L., Cohen, J. A., Ontaneda, D., & Rensel, M. R. (2019) · Multiple Sclerosis Journal - Experimental Translational and Clinical · doi:10.1177/2055217319891744 · Cited by 20
Yeh, T., Bai, Y., Hsu, J.-W., Huang, K.-L., Tsai, S., Chu, H., Liang, C., & Chen, M. (2021) · Journal of Affective Disorders · doi:10.1016/j.jad.2021.09.016 · Cited by 19
Uğuz, F., Sharma, V., Boyce, P. M., Clark, C. T., Galbally, M., Koukopoulos, A. E., Marsh, W., Stevens, A. W. M. M., & Viguera, A. C. (2023) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001740 · Cited by 17
Trends in valproate use in patients in Germany between 2009 and 2017
Jacob, L., Schmitz, B., Bohlken, J., & Kostev, K. (2018) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2018.12.002 · Cited by 16
Wang, M., Li, W., Tao, Y., & Zhao, L. (2019) · PeerJ · doi:10.7717/peerj.7115 · Cited by 17
“Four of the six published systematic reviews with meta-analyses assessed pregnancy outcomes in WWE (Meador et al., 2008) and the safety of AEDs for neurological development in children exposed during pregnancy and breast feeding (Veroniki et al., 2017b).”
BackgroundA practical guide to the use of psychotropic medications during pregnancy and lactation
Hardy, L. T., & Reichenbacker, O. L. (2019) · Archives of Psychiatric Nursing · doi:10.1016/j.apnu.2019.04.001 · Cited by 17
Thomson, M., & Sharma, V. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1854727 · Cited by 16
“anti-epileptic medications, including topiramate, for use in pregnancy [75,76].”
BackgroundEffects of Maternal Use of Antiseizure Medications on Child Development
Meador, K. J. (2022) · Neurologic Clinics · doi:10.1016/j.ncl.2022.03.006 · Cited by 21
Mehta, U., Smith, M., Kalk, E., Hayes, H., Swart, A., Tucker, L. M., Coetzee, R., Boulle, A., & Blockman, M. (2020) · Drug Safety · doi:10.1007/s40264-020-00987-4 · Cited by 15
“In addition, there is compelling evidence of an increased risk of autism and autism spectrum disorder in children exposed to VPA in utero [12–15].”
BackgroundWindsor, R. B., Sierra, M., Zappitelli, M. W., & McDaniel, M. (2020) · Children · doi:10.3390/children7120268 · Cited by 16
“with epilepsy taking oxcarbazepine [104,105].”
Levetiracetam as first‐line monotherapy for Idiopathic Generalized Epilepsy in women
Ballvé, A., Salas‐Puig, J., Quintana, M., Campos, D., Llauradó, A., Raspall‐Chaure, M., Fonseca, E., Abraira, L., Santamarina, E., & Toledo, M. (2021) · Acta Neurologica Scandinavica · doi:10.1111/ane.13389 · Cited by 15
Peron, A., Picot, C., Jurek, L., Nourredine, M., Ripoche, E., Ajiji, P., Cucherat, M., & Cottin, J. (2024) · BMC Pregnancy and Childbirth · doi:10.1186/s12884-023-06242-9 · Cited by 16
“In a previously published network MA [2], lamotrigine was associated with an increased occurrence of autism (traits and diagnosis combined) but no other neurodevelopmental defect.”
BackgroundMethodResultInfluentialMiller, D., Komanapalli, H., & Dunn, D. W. (2024) · Epilepsy & Behavior Reports · doi:10.1016/j.ebr.2024.100651 · Cited by 17
“…therapy during gestation are at increased risk for neurocognitive delays and should be screened at intervals, especially if the mother was maintained on Valproate, though there is conflicting evidence to support that Val-proate exposure in utero increases risk of ADHD in children [56,57].”
BackgroundYang, W., Braun, J. M., Vuong, A. M., Percy, Z., Xu, Y. Y., Xie, C., Deka, R., Calafat, A. M., Ospina, M., Burris, H. H., et al. (2022) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2022.159322 · Cited by 15
Valproate utilisation trends among girls and women from 2013 to 2018
Puteikis, K., Medžiaušaitė, I., & Mameniškienė, R. (2019) · Seizure · doi:10.1016/j.seizure.2019.07.001 · Cited by 14
Management of Bipolar Disorder in Pregnancy and Postpartum: A Clinicians’ Guide
Bergink, V., Suleiman, M., Hennen, M., & Robakis, T. K. (2025) · CNS Drugs · doi:10.1007/s40263-025-01202-7 · Cited by 15
“%) of children exposed to VPA in utero show neurodevelopmental difficulties, including cognitive, language and motor delays, lower IQ levels compared with exposure to other antiepilep-tics, behavioral challenges, and autism spectrum disorder [53–56].”
Prenatal, perinatal, postnatal risk factors, and excess screen time in autism spectrum disorder
Güneş, H., Tanıdır, C., Doktur, H., Yılmaz, S., Yıldız, D., Özbek, F., Bozbey, S., & Özşirin, G. (2023) · Pediatrics International · doi:10.1111/ped.15383 · Cited by 21
“31 Studies investigating the links between prenatal antidepressant exposure and autism present inconsistent results.”
ResultValproate use in women aged 15–44 years: an observational study in general practice
Beardsley, S. J., Dostal, I., Cole, J. N., Gutiérrez, A., & Robson, J. P. (2021) · BJGP Open · doi:10.3399/bjgpo.2020.0104 · Cited by 13
“There are strong associations with the development of autism where risk is estimated to be increased up to 17 times.(3,8) In utero valproate exposure is also associated with a significant decrease in intelligent quotient (IQ) of around 8 IQ points.”
BackgroundImpact of In Utero Exposure to Antiepileptic Drugs on Neonatal Brain Function
Tokariev, A., Breakspear, M. J., Videman, M., Stjerna, S., Scholtens, L. H., van den Heuvel, M. P., Cocchi, L., & Vanhatalo, S. (2021) · Cerebral Cortex · doi:10.1093/cercor/bhab338 · Cited by 14
“Consistent with previously known neurodevelopmental effects (Kellogg and Meador 2017; Veroniki et al. 2017), the AED-affected functional cortical networks were linked to newborn neurological performance and later language-related neurocognitive performance (Supplementary Fig.”
McTaggart, S., MacColl, G., Gronkowski, K., Wood, R., Leach, J. P., & Bennie, M. (2022) · BMJ Open · doi:10.1136/bmjopen-2021-058312 · Cited by 13
Management of Primary Headaches in Pregnancy
Saldanha, I. J., Roth, J. L., Chen, K. K., Zullo, A. R., Adam, G. P., Konnyu, K. J., Cao, W., Bhuma, M. R., Kimmel, H. J., Mehta, S., et al. (2020) · doi:10.23970/ahrqepccer234 · Cited by 17
He, L., Ke, M., Wu, W., Chen, J., Guo, G., Lin, R., Huang, P., & Lin, C. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14112367 · Cited by 12
“It is suggested that pregnant women should consider counseling to adjust to the safest treatment scheme [14].”
BackgroundOlstad, E. W., Nordeng, H., Sandve, G. K., Lyle, R., & Gervin, K. (2023) · Translational Psychiatry · doi:10.1038/s41398-023-02441-2 · Cited by 13
Pharmacotherapeutic strategies for drug-resistant epilepsy in children
Auvin, S., & Specchio, N. (2024) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2024.110139 · Cited by 17
“In utero, exposure to ASM could be responsible for an increased risk of malformation and developmental consequences (cognition and behavior) [32 – 35].”
Pregnant women, prescription, and fetal risk
Éléfant, É., Hanin, C., & Cohen, D. (2020) · Handbook of clinical neurology · doi:10.1016/b978-0-444-64150-2.00027-7 · Cited by 15
Јаnkovic, S., & Janković, S. V. (2020) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2020.1795125 · Cited by 12
RYBAKOWSKI, J. K., Cubała, W. J., Gałecki, P., Rymaszewska, J., Samochowiec, J., Szulc, A., & Dudek, D. (2019) · Psychiatria Polska · doi:10.12740/pp/103555 · Cited by 14
“The latest analysis showed that the use of oxcarbazepine during pregnancy may be associated with an increased risk of autism in childhood [26].”
Pharmacological treatment of bipolar disorder in pregnancy
Singh, S., & Deep, R. (2022) · Indian Journal of Pharmacology · doi:10.4103/ijp.ijp_407_21 · Cited by 10
“[28] Clinical point • Risk appears low, but more data are needed.”
Louchet, M., Collier, M., Beeker, N., Mandelbrot, L., Sibiude, J., Chouchana, L., & Tréluyer, J. (2024) · PLoS ONE · doi:10.1371/journal.pone.0295897 · Cited by 15
“Foremost, prenatal exposure was also shown to be related to neurodevelopmental disorders such as autism and attention-deficit hyperactivity disorders [3–5].”
Jackson, B. L., Shafique, S., Natale, B. V., Natale, D. R. C., & Winn, L. M. (2024) · Reproductive Toxicology · doi:10.1016/j.reprotox.2024.108551 · Cited by 12
Peedicayil, J. (2021) · Current Neuropharmacology · doi:10.2174/1570159x19666210920091036 · Cited by 10
Vaccaro, C., Shakeri, A., Czaplinski, E., & Eltonsy, S. (2020) · Journal of Population Therapeutics and Clinical Pharmacology · doi:10.15586/jptcp.v27i4.722 · Cited by 28
Rotem‐Kohavi, N., Keane, J., Clarke, G. A., Dinan, T. G., Cryan, J. F., McCarthy, F. P., Oberlander, T. F., & O’Mahony, S. M. (2021) · Springer eBooks · doi:10.1007/978-3-030-60159-1_8 · Cited by 9
Neurodevelopmental outcomes in children exposed prenatally to levetiracetam
Alsfouk, B. A. A. (2022) · Therapeutic Advances in Drug Safety · doi:10.1177/20420986221088419 · Cited by 9
Demailly, R., Escolano, S., Haramburu, F., Tubert‐Bitter, P., & Ahmed, I. (2020) · Drug Safety · doi:10.1007/s40264-020-00916-5 · Cited by 13
Prenatal Exposure to Gabapentin Alters the Development of Ventral Midbrain Dopaminergic Neurons
Alsanie, W. F., Abdelrahman, S., Alhomrani, M., Gaber, A., Habeeballah, H. H., Alkhatabi, H. A., Felimban, R. I., Hauser, C. A. E., Tayeb, H. H., Alamri, A. S., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.923113 · Cited by 13
“This has made it necessary to develop optimum treatments with safe regimens (Veroniki et al., 2017).”
BackgroundAffective disorders: A question of continuing treatment during pregnancy (Review)
Trifu, S. C., Popescu, A., & Marian, M. (2020) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2020.8989 · Cited by 11
“Alone, or combined with another antiepileptic drug, it is associated with the greatest risk of teratogenicity of all the mood stabilizers (55).”
BackgroundVélez, M. M., & Meador, K. J. (2019) · Springer eBooks · doi:10.1007/978-3-030-04245-5_14 · Cited by 8
Tachibana, M., Hashimoto, T., TANAKA, M., Watanabe, H. A., Sato, Y., Takeuchi, T., Terao, T., Kimura, S., Kôyama, A., Sachie, E., et al. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.00250 · Cited by 6
Thomas, S. V., Salim, S., Jacob, N. S., Jose, M., Salini, R. A., Selvaraj, S., Gomez, T. S., Sreedharan, H., & Jeemon, P. (2022) · Seizure · doi:10.1016/j.seizure.2022.06.005 · Cited by 8
Women with drug‐resistant epilepsy: Surgery or pregnancy first?
Kandraju, S. S., Jose, M., Salini, R. A., Pavithran, V., Peedicail, J. S., Menon, R. N., Radhakrishnan, A., Cherian, A., Abraham, M., Vilanilam, G. C., et al. (2020) · Epilepsia · doi:10.1111/epi.16613 · Cited by 7
Zosen, D., Austdal, L. P. E., Bjørnstad, S., Lumor, J. S., & Paulsen, R. E. (2021) · Neurotoxicology and Teratology · doi:10.1016/j.ntt.2021.107057 · Cited by 8
Trends in Prenatal Exposure to Antiseizure Medications Over the Past Decade: A Nationwide Study
Shahriari, P., Drouin, J., Miranda, S., Bougas, N., Botton, J., & Dray‐Spira, R. (2025) · Neurology · doi:10.1212/wnl.0000000000213933 · Cited by 9
Schäfer, M., & Brandl, E. J. (2020) · Springer eBooks · doi:10.1007/978-3-319-56015-1_49-1 · Cited by 7
Fauvelle, K., & Bigna, J. J. (2022) · Drug Safety · doi:10.1007/s40264-022-01234-8 · Cited by 6
Birth outcomes in pregnant women with epilepsy: A Nationwide multicenter study from Türkiye
Peköz, M. T., Aslan, K., Güveli, B. T., Gürses, C., Yenı, S. N., Bozdemir, H., Güler, S. K., Ataklı, D., Gül, G., Eren, F., et al. (2023) · Epilepsia · doi:10.1111/epi.17692 · Cited by 8
Pharmacoepidemiological research for the development and evaluation of drugs in pediatrics
Kaguelidou, F., Durrieu, G., & Clavenna, A. (2019) · Therapies · doi:10.1016/j.therap.2018.09.077 · Cited by 8
Metadata
- Authors
- Veroniki, A. A., Rios, P., Cogo, E., Straus, S. E., Finkelstein, Y., Kealey, R., Reynen, E., Soobiah, C., Thavorn, K., Hutton, B., Hemmelgarn, B. R., Yazdi, F., D'Souza, J., MacDonald, H., & Tricco, A. C.
- Affiliations
- St. Michael's Hospital (CA)
- University of Toronto (CA)
- University of Ottawa (CA)
- University of Calgary (CA)
- Corresponding author
- Tricco, Andrea C
- ORCID
- Venue
- BMJ Open
- Publisher
- BMJ
- Published
- 2017-07
- Volume
- 7
- Issue
- 7
- Pages
- e017248
- ISSN
- 2044-6055 (ISSN-L)
- PMC
- PMC5642793
- OpenAlex
- W2738349700
- Semantic Scholar
- 1927e1fe6c2f75e9ef202e803e3ecae9efc82d24
- Cited by
- 222
- References
- 50
- Citations by year
- 2026: 7 · 2025: 22 · 2024: 22 · 2023: 14 · 2022: 41 · 2021: 29 · 2020: 47 · 2019: 26 · 2018: 12 · 2017: 1
- FWCI
- 4.41
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc
- Locations
- BMJ Open (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- HighWire Press Open Archive (submittedVersion)
- Funders
- CIHR/DSEN New Investigator Award in Knowledge Synthesis
- Tier 1 Canada Research Chair in Knowledge Translation
- Tier 2 Canada Research Chair in Knowledge Synthesis
- Canadian Institutes for Health Research/Drug Safety and Effectiveness Network
- Banting Postdoctoral Fellowship Program from the CIHR
- Alberta Heritage Foundation for Medical Research
- Topics
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmacological Effects and Toxicity Studies
- Health Sciences › Medicine › Clinical Neurology › Epilepsy research and treatment
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Fetal and Pediatric Neurological Disorders
- Keywords
- antiepileptic drugs, prenatal drug exposure, breastfeeding, developmental neurotoxicity, autism spectrum disorder, cognitive delay, valproic acid, lamotrigine, oxcarbazepine, attention deficit hyperactivity disorder, neonatal seizures, epilepsy in pregnancy, drug safety comparison
- MeSH terms
- Lamotrigine, Oxcarbazepine, Anticonvulsants, Autistic Disorder, Bayes Theorem, Breast Feeding, Carbamazepine, Child, Epilepsy, Female, Humans, Pregnancy, Pregnancy Complications, Prenatal Exposure Delayed Effects, Triazines, Valproic Acid, Observational Studies as Topic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.